The FDA has approved Keytruda (pembrolizumab; Merck), a programmed death receptor-1 -blocking antibody, as monotherapy for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
Researchers assessed whether adherence to oral antidiabetic medication was a modifiable prognostic factor in patients with CRC and preexisting diabetes.
The FDA has approved Opdivo® (nivolumab; Bristol Myers Squibb) for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
Early results warrant further exploration of intrahepatic injection of T-VEC, a genetically modified oncolytic HSV-1, in combination with pembrolizumab.
Phase 3 clinical trial of combination shows survival and quality-of-life benefits vs the standard of care, sorafenib, leading to the regimen’s expedited regulatory approval.
Binimetinib plus imatinib in the frontline setting appeared to improve outcomes for patients with advanced gastrointestinal stromal tumor, warranting further study.
Antibody-drug conjugate trastuzumab deruxtecan demonstrated promising efficacy against relapsed, metastatic, HER2+ CRC according to results from a phase 2 trial.
A phase 2/3 trial found that patients with advanced HCC who received donafenib had significantly longer OS compared with sorafenib, the standard first-line therapy.
Adjuvant treatment of GIST with imatinib for 36 months prolonged OS and RFS compared with 12 months of imatinib, according to data from nearly 10 years of follow-up.
These study findings show that weight loss occurred early among patients with advanced gastric cancer and was associated with shorter overall survival.
